Patent Law Loophole Offers Affordable Drug to Patients

A generic version of a vital cystic fibrosis medication is now accessible at a greatly reduced cost due to a gap in patent law. This development offers new hope to many families who previously struggled to afford such treatment.

Josua Lottering and his mother traveled from South Africa to Bangladesh with high hopes. They aimed to acquire a year’s supply of a crucial drug. The drug, Trikafta, created by Vertex Pharmaceuticals of Boston, is priced at $346,000 annually in the U.S. Despite his struggle with reduced lung function and the humid air exacerbating his condition, Josua felt optimistic.

Trikafta is renowned for its ability to improve the quality of life of cystic fibrosis sufferers in developed regions. It has generated substantial revenue, amounting to $49 billion since its 2019 debut. Nevertheless, Vertex has not permitted its distribution in many low-income countries and has actively blocked cheaper generic alternatives to maintain higher pricing in affluent markets.

A pharmaceutical company in Bangladesh has now reverse engineered Trikafta, branding its version as ‘Triko’, and selling it for significantly less by using a particular aspect of global patent law. This initiative has provided families like the Lotterings access to life-saving treatment they could not previously afford.

Recently, the Lotterings and others made their way to Dhaka to purchase Triko, the freshly manufactured product from Beximco Pharmaceuticals. Their journey underscores the ongoing global challenges in accessing essential medications.